Epithelial cells that have been damaged
by the EspC toxin. Credit: La Trobe University
Scientists
at La Trobe University have discovered how a diarrhea-causing strain of
bacteria uses "molecular scissors" to cut open and destroy gut cells,
leading to severe illness and sometimes death.
Published in Gut Microbes, the research reveals for the first time the
three-dimensional structure of a toxin secreted by enteropathogenic E. coli
(EPEC) bacteria, and shows how the bacteria use the toxin to invade and destroy
the epithelial cells that line the gut.
The toxin, which is an enzyme called
EspC, destroys the cells by cutting up their internal protein structure.
La Trobe University scientist Professor
Begoña Heras, who co-led the research, said understanding how the dangerous
bacterial toxin worked was critical for the future development of new, targeted
drugs to treat EPEC infections in the face of rising antimicrobial resistance.
"Many strains of E. coli, including
EPEC, which is a major cause of diarrheal disease, are becoming increasingly
resistant to the antibiotics commonly used to treat these infections,"
Professor Heras said.
"This is alarming as 1.3 million
children under the age of 5 die each year from diarrheal illnesses due to the
associated severe dehydration and loss of essential electrolytes.
"Revealing the structure of EPEC's
toxic weapon and showing how it destroys cells, brings us one step closer to
stopping this deadly disease which affects millions worldwide."
There are more than five types of E.
coli that damage epithelial cells in different ways to cause gut infection.
These include STEC, which was
responsible for the recent salad spinach recall and uses Shiga toxin to invade
gut cells, and EPEC—the subject of this study—which uses the toxin EspC and is
the leading cause of diarrhea in children and babies worldwide.
Currently, infections caused by the many
diverse strains of E. coli are typically treated with broad-spectrum antibiotics. However, these drugs kill both harmful and
beneficial gut bacteria, and E. coli's rapid adaptation ability means these
pathogens are becoming resistant to many antibiotics.
Dr. Jason Paxman, who co-led the
research with Professor Heras, said treating E. coli infections had become
increasingly difficult, with clinicians frequently needing to use strong
antibiotics of last resort, meaning there are no other treatments available.
"We're running out of options to
treat bacterial diseases, with some bacterial pathogens now resistant to all
antibiotics," Dr. Paxman said.
"New antibiotics are still being
developed, but the pace is extremely slow and when they become available,
they're often put in a stewardship and only used when absolutely necessary, as
bacteria can develop resistance within just a few years.
"This is a huge issue, as most
traditional antibiotics do not target specific bacteria—which means a single
antibiotic can apply selective pressure across many bacterial species, whether it's E.
coli, Staphylococcus aureus and others, leading to widespread resistance to the
one type of drug."
Professor
Heras, Dr. Paxman and the paper's first author, Dr. Akila Pilapitiya worked
with a multidisciplinary team of researchers at the La Trobe Institute of
Molecular Science (LIMS) and La Trobe's School of Agriculture, Biomedicine and
Environment (SABE).
Dr. Pilapitiya, who worked on the
research as a part of her Ph.D., said working with a multidisciplinary team was
essential to understand how EPEC used EspC as a molecular weapon.
"It was already known that EPEC
used EspC as a toxin, but little was known about its structure and how it
worked," Dr. Pilapitiya said.
"By using a multidisciplinary
approach, I was able to determine the 3D structure of EspC toxin, which shows
how it's built and the role each of its parts play to make it work.
"This knowledge provides a
foundation for designing new, more specific drugs that can disarm EPEC, combat
diarrheal infections and protect our gut cells from damage."
Professor Heras hopes the
multidisciplinary approach can pave the way for other researchers to find new
potential treatments for many harmful pathogens.
"Our work shows how combining
different areas of science can help solve complex research questions and
support the development of new drugs to protect human health," Professor
Heras said.
Professor Heras, Dr. Paxman and Dr. Pilapitiya are members of La Trobe's School of Agriculture, Biomedicine and Environment (SABE) and the La Trobe Institute for Molecular Science (LIMS), where Professor Heras is co-lead of the Infection and Immunity Program.
No comments:
Post a Comment